**Claims**

1. Use of a chemical composition in the manufacture of a medicament for the treatment of hot flashes, the chemical composition comprising a dopamine agonist capable of binding to $D_2$, $D_3$, or $D_4$ dopamine receptors.

2. The use of a chemical composition as set forth in claim 1 wherein the medicament is in a form for administration selected from the group consisting a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition.

3. Use of a chemical composition in the manufacture of a medicament for the treatment of hot flashes, the composition comprising a dopamine agonist capable of binding to $D_2$, $D_3$, or $D_4$ dopamine receptors,

wherein the medicament is to be administered to a person experiencing hot flashes in combination with a further composition that comprises an alpha-2-adrenergic agonist capable of binding to alpha-2-adrenergic receptor.

4. The use of a chemical composition as set forth in claim 3, wherein the medicament is in a form for administration selected from the group consisting a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition, and

the further chemical composition that comprises an alpha-2-adrenergic agonist is to be provided in a form for administration selected from the group consisting a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition.

5. Use of a chemical composition in the manufacture of a medicament for the treatment of hot flashes, the chemical composition comprising an alpha-2-adrenergic agonist capable of binding to alpha-2-adrenergic receptor,

wherein the medicament is to be administered to a person experiencing hot flashes in combination with a further composition that comprises a dopamine agonist capable of binding to $D_2$, $D_3$, or $D_4$ dopamine receptors.

6. The use of a chemical composition as set forth in claim 5, wherein the medicament is in a form for administration selected from the group consisting of a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition, and

the further composition that comprises a dopamine agonist is to be provided in a form for administration selected from the group consisting a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition.

7. Use of a chemical composition in the manufacture of a medicament for the treatment of hot flashes, the composition comprising a dopamine agonist capable of binding to $D_2$, $D_3$, or $D_4$ dopamine receptors and an alpha-2-adrenergic agonist capable of binding to alpha-2-adrenergic receptor.

8. The use of a chemical composition as set forth in claim 7, wherein the medicament is in a form for administration selected from the group consisting of a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition.

9. A composition suitable for treatment of hot flashes, comprising: a substance that is a dopamine agonist capable of binding to $D_2$, $D_3$, or $D_4$ dopamine receptors, and a substance that is an alpha-2-adreneric agonist.

10. A composition as set forth in claim 9 comprising a form which is capable of administration to an individual as a pill.

11. A composition as set forth in claim 10 comprising a form which is capable of administration to an individual as a pill and wherein the dopamine agonist and the alpha-2-adreneric agonist are separately placed within the pill.

12. A composition as set forth in claim 10 comprising a form which is capable of administration to an individual as a pill and wherein the dopamine agonist and the alpha-2-adreneric agonist are combined within the pill.

13. A composition as set forth in claim 9 comprising a form which is capable of administration to an individual orally as a liquid.

14. A composition as set forth in claim 9 comprising a form which is capable of administration to an individual intravenously as a liquid.

15. A composition as set forth in claim 9 comprising a form which is capable of administration to an individual by inhalation.

16. A composition as set forth in claim 9 wherein the substance that is a dopamine agonist capable of binding to $D_2$, $D_3$, or $D_4$ dopamine receptors is selected from the group consisting of ropinirole, rotigitine, pramipexole, piribedil, venlafaxine, paroxetine, gabapentin, and

pregabilin and the substance that is an alpha-2-adreneric agonist is selected from the group consisting of tizanidine and clonidine.